Prevalence of Meibomian Gland Dysfunction in the Upper Eyelid Among Postmenopausal Women with Primary Acquired Nasolacrimal Duct Obstruction

Category	Detail
Condition
Key Mechanisms	Idiopathic inflammation and fibrosis of the nasolacrimal duct leading to epiphora; hormonal factors contributing to meibomian gland dysfunction; chronic inflammation and elevated tear cytokine levels exacerbating MGD.
Target Population
Care Setting

PANDO predominantly affects postmenopausal women, with a female-to-male incidence ratio of up to 3:1.
Meibomian gland dysfunction (MGD) is a significant factor in evaporative dry eye disease, particularly in postmenopausal individuals.
20% to 27% of patients with lacrimal duct obstruction report dry eye symptoms post-surgery.
Structural and functional alterations in meibomian glands are observed in postmenopausal women with PANDO.
The study aims to investigate the differential involvement of meibomian glands in upper and lower eyelids.
Emerging evidence supports a potential association between PANDO and ocular surface damage.

Diagnosis of PANDO based on epiphora, confirmed nasolacrimal duct obstruction, and absence of secondary causes.

Evaluate ocular surface status in patients with PANDO during episodes of epiphora.
Consider anatomical differences between upper and lower eyelids when assessing MGD.

Assess meibomian gland loss and tear film stability in postmenopausal women with PANDO.

Patients may have pre-existing ocular surface damage before surgical intervention for PANDO.

Postmenopausal women diagnosed with PANDO.

Targeted therapeutic strategies may be developed based on the correlation between meibomian gland parameters and tear film function.

Conduct thorough ocular examinations to assess meibomian gland function and tear film stability.
Consider hormonal factors when evaluating postmenopausal women with PANDO.
Evaluate tear film stability in relation to meibomian gland function.